Heartline·Cardiovascular desk November 13, 2026 · 56 plain-English notes

Evidence-led notes on the heart, the vessels and the habits that shape both.

Metabolic Health · Note 24

Energy drinks and stimulant supplements linked to several serious heart risks

A review of an FDA safety database found energy drinks and stimulant supplements repeatedly named in reports of cardiac arrest, heart attacks, arrhythmias and other serious cardiac events.

Cardiovascular Business November 3, 2026 RSS metadata basis
Abstract heartbeat trace artwork
Schematic artwork — not clinical data. The trace is generated for layout, not measurement.

Energy drinks and stimulant-based supplements occupy an odd regulatory space. They are sold as groceries or dietary products rather than medicines, yet the doses of caffeine and other stimulants they deliver can be large, and they are consumed by teenagers and young adults who may also have undiagnosed cardiac conditions.

The review described by Cardiovascular Business turned to the FDA's safety database and found that these products appeared commonly in reports involving cardiac arrest, heart attacks, ventricular arrhythmias, palpitations, chest pain and fainting. The pattern is consistent with what the pharmacology would predict: stimulants raise heart rate and blood pressure and can destabilise the heart's electrical rhythm.

Spontaneous reports are a signal, not proof. They are filed voluntarily, are unevenly complete and cannot establish how often an event follows exposure. What they do support is a case for clearer labelling, better counselling of patients with known arrhythmia or hypertension, and clinical attention when a young patient presents with unexplained palpitations.

Why it mattersStimulant drinks and supplements recur in serious cardiac reports.

Keep in mind

  • Events include arrest, infarction and ventricular arrhythmia.
  • Voluntary reporting shows signal, not causation.

Source and reuse

This is an independent editorial summary written for Heartline. It is not a verbatim reproduction and does not reproduce paywalled text. Reporting, data and quotations belong to Cardiovascular Business. Read the original at the link provided.

Metadata basis: the publisher’s public RSS feed and the abstract it exposes. Where the full article could not be accessed, this note is explicitly metadata-based and limited to what the feed disclosed. It is not medical advice.

Read the original at Cardiovascular Business →